Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun;32(6):595-607.
doi: 10.1038/s41417-025-00905-9. Epub 2025 Apr 30.

Glioblastoma-associated macrophages in glioblastoma: from their function and mechanism to therapeutic advances

Affiliations
Review

Glioblastoma-associated macrophages in glioblastoma: from their function and mechanism to therapeutic advances

Yuqin Zhang et al. Cancer Gene Ther. 2025 Jun.

Abstract

Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor in adults and has high mortality rates worldwide. GBM progression, treatment, and prognosis are influenced by the tumor microenvironment (TME), which includes immune, stromal, and tumor cells. Among them, glioblastoma-associated macrophages (GAMs) act as key regulators of GBM pathobiology. GAMs exhibit remarkable plasticity, as they can exhibit both protumor and antitumor effects. However, their function is determined by polarization and the TME. In this review, we provide a comprehensive overview of the current understanding of the biology of GAMs in GBM, including their origins, phenotypic diversity, and functional roles. We discuss the intricate crosstalk between GAMs and tumor cells, as well as other immune and stromal components, and highlight the mechanisms underlying GAM-mediated tumor progression, invasion, angiogenesis, and immune system evasion. Furthermore, we explore the therapeutic implications of targeting GAMs in GBM and discuss emerging strategies aimed at reprogramming GAMs toward an antitumorigenic phenotype or selectively depleting protumorigenic subsets. The final aim is to develop innovative therapeutic approaches that disrupt GBMs. By leveraging our increased understanding of GAM biology, we lay the foundation for transformative advances in GBM treatment to improve patient prognosis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests. Consent for publication: All the authors have agreed on the contents of the manuscript.

Similar articles

Cited by

References

    1. Weller M, Le Rhun E. How did lomustine become standard of care in recurrent glioblastoma? Cancer Treat Rev. 2020;87:102029. - PubMed - DOI
    1. Chen B, Zhou X, Yang L, Zhou H, Meng M, Zhang L, et al. A cuproptosis activation scoring model predicts neoplasm-immunity interactions and personalized treatments in glioma. Comput Biol Med. 2022;148:105924. - PubMed - DOI
    1. Jiang T, Nam DH, Ram Z, Poon WS, Wang J, Boldbaatar D, et al. Clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett. 2021;499:60–72. - PubMed - DOI
    1. Wang LJ, Lv P, Lou Y. Alarm signal S100-related signature is correlated with tumor microenvironment and predicts prognosis in glioma. Dis Markers. 2022;2022:4968555. - PubMed - PMC
    1. Seyfrid M, Maich WT, Shaikh VM, Tatari N, Upreti D, Piyasena D et al. CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment. J Immunother Cancer 2022;10:e003289.

MeSH terms

LinkOut - more resources